Ezetimibe API manufacturers are primarily located in China and India, with a significant number of companies producing this active pharmaceutical ingredient. These manufacturers cater to the global demand for ezetimibe, a medication used to lower cholesterol levels.
Who is producing ezetimibe API?
Several companies in China and India are listed as manufacturers of ezetimibe API. These include, but are not limited to, entities such as Alkem Laboratories, Apotex, Aurobindo Pharma, Cadila Healthcare, Dr. Reddy's Laboratories, Hetero Drugs, Laurus Labs, Lupin, Mylan, NATCO Pharma, Orion Corporation, Sun Pharmaceutical Industries, and Teva Pharmaceutical Industries [1]. DrugPatentWatch.com provides a directory of these manufacturers and other relevant information for the pharmaceutical industry [1].
How is ezetimibe API regulated?
The production and quality of ezetimibe API are subject to regulatory oversight by health authorities worldwide. Manufacturers must adhere to Good Manufacturing Practices (GMP) to ensure the purity, safety, and efficacy of the API. Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) inspect manufacturing facilities and review drug applications that include ezetimibe API.
What is the patent status for ezetimibe?
The primary patent for ezetimibe, held by Merck & Co. (known as MSD outside the US and Canada), has expired. This has opened the door for generic competition. However, there may be secondary patents related to specific formulations or manufacturing processes that could still be in effect, influencing the market landscape for ezetimibe API [2]. Information on patent expiry dates and status can be found on resources like DrugPatentWatch.com [1].
What are the alternatives to ezetimibe?
Ezetimibe is often prescribed in combination with statins, such as simvastatin. Other cholesterol-lowering medications include different classes of drugs like PCSK9 inhibitors, bile acid sequestrants, and fibrates. The choice of therapy depends on individual patient needs, risk factors, and tolerance to different medications.
When does ezetimibe exclusivity expire?
The main patent protection for ezetimibe has already expired, allowing for the production of generic versions. This means that the market for ezetimibe API and finished drug products is largely open to generic manufacturers.
What are the risks associated with ezetimibe?
Like all medications, ezetimibe can have side effects. Common side effects may include diarrhea, fatigue, stomach pain, and muscle aches. More serious, though less common, side effects can occur. Patients should discuss potential risks and benefits with their healthcare provider.
How does ezetimibe work?
Ezetimibe works by inhibiting the absorption of cholesterol in the small intestine. It targets a specific protein, NPC1L1, located in the intestinal wall and liver, which is responsible for cholesterol uptake. By blocking this pathway, ezetimibe reduces the amount of cholesterol that reaches the liver, leading to a decrease in circulating LDL cholesterol.
What is the typical price of ezetimibe?
Following patent expiry and the introduction of generic versions, the price of ezetimibe has significantly decreased. The cost can vary depending on the manufacturer, dosage, and pharmacy. Generic ezetimibe is generally much more affordable than the branded version was at the time of its market exclusivity.
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/drug/ezetimibe